<DOC>
	<DOCNO>NCT00002031</DOCNO>
	<brief_summary>To evaluate effect application Dinitrochlorobenzene ( DNCB ) number , morphology , antigen expression epidermal Langerhans cell AIDS AIDS relate complex ( ARC ) patient .</brief_summary>
	<brief_title>Evaluation Epidermal Langerhans Cell Population AIDS / ARC Patients Topical Application Potent Contact Allergen ( 1-Chloro-2,4-Dinitro-Chlorobenzene ) ( DNCB )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : Stage III IV HIV infection . Provide inform consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Kaposi 's sarcoma lesion propose treatment site . Liable require radiation chemotherapy course study . Not likely survive length study . Obvious ultravioletirradiated skin damage treatment area anyone recent UV exposure likely exposure ( e.g . : holiday tan obtain Hawaii , member UV box tan salon , etc . ) Allergy lidocaine . Concurrent Medication : Excluded : Other Immunomodulators . Concurrent Treatment : Excluded : Radiation . Patients follow exclude : Kaposi 's sarcoma lesion propose treatment site . Liable require radiation chemotherapy course study . Not likely survive length study . Obvious ultravioletirradiated skin damage treatment area . Allergy lidocaine . Prior Medication : Excluded : Prior DNCB therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 1990</verification_date>
	<keyword>Langerhans Cells</keyword>
	<keyword>Dinitrochlorobenzene</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>